- KR₩73bn
- KR₩92bn
- KR₩56bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.64% | ||
| Return on Equity | -15.43% | ||
| Operating Margin | -39.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 56,155.49 | 26,895.99 | 18,613.35 | 19,098.33 | 55,750.07 | n/a | n/a | 10.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -21.44 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SMeDi Co Ltd, formerly The MediPharm Co Ltd, is a Korea-based company primarily engaged in the pharmaceutical distribution business. The Company operates through five segments. The Pharmaceuticals Business segment is engaged in the distribution of pharmaceuticals including recapsules and tablets. The Medical Business segment is engaged in the distribution of medical devices and medical supplies. The Wireless Device segment is engaged in the manufacture of wearable wireless devices. The Video Content segment is engaged in the production of video products. The Investment segment is engaged in the management consulting and investment businesses.
Directors
- Geun Hyeong Lee CEO (49)
- Jin Su Jung OTH (59)
- Gwan Sik Choi DRC (42)
- Su Gyeong Kim DRC (64)
- Seung Yeol Lee DRC (33)
- Byeong Yil Seo DRC (45)
- Gyu Seong Jung NID (45)
- Cheol Beom Lee NID (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 1st, 2009
- Public Since
- December 30th, 2009
- No. of Shareholders
- 25,759
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 142,775,209
- Address
- 156, Byeongjeomjungang-ro, HWASEONG, 18404
- Web
- http://www.chorokbaemhc.com/
- Phone
- +82 221861300
- Auditors
- Donghyun Accounting Corp
Upcoming Events for 118000
Similar to 118000
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 19:20 UTC, shares in SMeDi are trading at KR₩511. This share price information is delayed by 15 minutes.
Shares in SMeDi last closed at KR₩511 and the price had moved by -23.62% over the past 365 days. In terms of relative price strength the SMeDi share price has underperformed the FTSE Developed Asia Pacific Index by -20.27% over the past year.
There is no consensus recommendation for this security.
SMeDi does not currently pay a dividend.
SMeDi does not currently pay a dividend.
SMeDi does not currently pay a dividend.
To buy shares in SMeDi you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩511, shares in SMeDi had a market capitalisation of KR₩73bn.
Here are the trading details for SMeDi:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 118000
Based on an overall assessment of its quality, value and momentum SMeDi is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SMeDi. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +15.97%.
As of the last closing price of KR₩511, shares in SMeDi were trading +12.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SMeDi PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩511.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SMeDi's management team is headed by:
- Geun Hyeong Lee - CEO
- Jin Su Jung - OTH
- Gwan Sik Choi - DRC
- Su Gyeong Kim - DRC
- Seung Yeol Lee - DRC
- Byeong Yil Seo - DRC
- Gyu Seong Jung - NID
- Cheol Beom Lee - NID